11 news items
What's Going On With FibroGen Stock Tuesday?
FGEN
REGN
4 Jun 24
Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
ALBT
ANNX
BARK
4 Jun 24
) gained 18.6% to $1.46 in pre-market trading after the company announced announced that the FDA cleared its Investigational New Drug of FG-3165. Also
FibroGen Stock Is Surging After The Bell: What's Going On?
FGEN
REGN
3 Jun 24
in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
. Earlier today, FibroGen separately announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN
3 Jun 24
Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized
wu4n5rmekqdh45vket6ttkk2dwpsy6ccdp1xotlm
BNTX
CTMX
FGEN
3 Jun 24
investigational, masked, conditionally activated PROBODY T-cell engager, CX-904, demonstrating a favorable safety profile and confirmed anti-cancer
3pc8on0fwaiisn48ujywik at226
BNTX
CTMX
FGEN
3 Jun 24
for its investigational, masked, conditionally activated PROBODY T-cell engager, CX-904, demonstrating a favorable safety profile and confirmed anti
iqjwjdosdl
FGEN
23 May 24
of the investigator-sponsored Phase 1b/2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti
bj0otrt7wupgthpjpofdnmwv1eosqv vppukdkeg2ocjgasp3j0soq23
FGEN
6 May 24
Pipeline Initial data from Phase 1 investigator-initiated combination study of FG-3246 with enzalutamide in metastatic castration
0150pj la4x7od
FGEN
24 Apr 24
anti-tumor activity in both preclinical and clinical studies. FG-3246 is currently in an ongoing investigator-initiated Phase 1b/2 study being conducted
823ied1knu950zl1aqb2xmjdg917nvchpi5w1ktfdmpyzbvc6qm3zlw bd
FGEN
2 Apr 24
Investigator of the study. "The observed median radiographic progression free survival of 8.7 months in patients treated with a starting FG-3246 dose
- Prev
- 1
- Next